Stay updated with breaking news from Eric Elenko. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PureTech Health plc has been awarded $11.4 million (£8.9 million) from the US Department of Defense (DoD) to advance its therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders.
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- PureTech Health PLC - Boston, US-based biotherapeutics...
A Boston-based biotherapeutics company has announced initiation of a phase 2a proof-of-concept clinical trial of an oral prodrug of endogenous allopregnanolone in healthy volunteers using a validated clinical model of anxiety. According to a release from PureTech Health plc, LYT-300 holds the potential to treat a range of neurological and neuropsychiatric disorders including anxiety disorders and
PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders. The Phase 2a... | June 21, 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) – Investment analysts at Zacks Research lowered their FY2025 EPS estimates for Karuna Therapeutics in a research note issued on Thursday, June 15th. Zacks Research analyst S. Ganoria now forecasts that the company will earn ($5.07) per share for the year, down from their previous forecast of ($4.81). […]